The sanction fell. The Paris Court of Appeals announced on Wednesday, September 24, after having sentenced the Sanofi and Sanofi Winthrop industry to pay 150.7 million euros in the National Health Insurance Fund (CNAM) as damages, in compensation for damages suffered due to anti -competitive practices.
The Court’s decision confirms that the competence authority, which had sanctioned the two companies in 2013 “for having implemented a denigration strategy against the generic of Plavix,” according to a statement.
Plavix, an anti -notation plate used to prevent cardiovascular accidents in adults who have already had a heart attack or spill, is one of the best medications sold in the world and the first position for the reimbursement of health insurance in France. The French pharmaceutical group is convicted of having implemented, between September 2009 and January 2010, “a denigrating communication strategy” aimed at encouraging doctors to promote Plavix and their own generic to the detriment of competitors, it emphasizes the court.
Too high safety reimbursements
The CNM had seized the Commercial Court of Paris, believing that Sanofi’s actions had led to higher reimbursements and grant greater remuneration to pharmacists.
Princeps drug prices, known as a brand in everyday language, are in fact more expensive than their generic ones, since they were the first to market. According to public drugs of medicines, the box of 30 Plavix tablets costs 11.20 euros in pharmacies, including dispensing rates and is 65% reimbursed by health insurance. In the same picture, marketed by its generic under the name of the active ingredient, that is, clopidogrel, is expensive: 8.77 euros.
Source: BFM TV
